国产基因工程干扰素α1治疗慢性乙型肝炎的临床研究

２２５例慢性乙型肝炎分三组治疗，Ａ和Ｂ组７４例配对随机用干扰素α１及安慰剂双盲对照观察，Ｃ组１５１例为干扰素α１４０微克连用三个月，ＨＢｅＡｇ、ＨＢＶ－ＤＮＡ、ＨＢｅＡｇ和ＨＢＶ－ＤＮＡ双转阴率及抗ＨＢｅ转阳率分别为４０．５％、５７．１％、３９．３％及２９．７％，与对照组差异有非常显著性（Ｐ＜０．０１）。扩大治疗组结果与Ａ组相似，均明显优于对照组。治疗组随访半年和一年ＨＢｅＡｇ及ＨＢＶ－ＤＮＡ转阴率与治疗结束时相似，表明有较持久的效果。     

ONCOGENJC HYPOPHOSPHATEMIC OSTEOMALACIA ASSOCIATED WITH A GIANT CELL TUMOUR OF A TENDON SHEATH

Abstract We report a case of oncogenic hypophosphatemic osteomalacia, a rare form of osteomalacia, secondary to a diffuse giant cell tumour of tendon sheath. Possible pathogenic factors are discussed in the light of previously described clinical and experimental observations.     

PROSPECTIVE EVALUATION OF A FLEXIBLE PROTOCOL FOR STARTING TREATMENT WITH WARFARIN AND PREDICTING ITS MAINTENANCE DOSE

We have evaluated a flexible warfarin dose induction protocol by monitoring its performance in 100 elderly inpatients. The protocol (designed by Fennerty et al., has two aims: (a) to move the prothrombin time (PT) ratio smoothly and quickly into its therapeutic range, and (b) to predict the steady-state warfarin requirement from the PT ratio measured on the fourth treatment day. It proved simple to use and reasonably successful, since after four days, 67/100 patients had achieved a therapeutic level of PT ratio, nine exceeded the therapeutic range, and 24 remained sub-therapeutic, while none had bled due to excessive anticoagulation. Maintenance dose prediction was tested by comparing the predicted and observed maintenance doses in patients within the ‘therapeutic range’ of PT ratio after various median times of treatment. After ten days, the observed dose was within 1 mg of that predicted in 65/86 patients (76%). This proportion became 57/77 (74%) after 18 days, and 49/79 (62%) after 34 days.     

A PHASE Ml STUDY OF CYTOSINE ARABINOSIDE, DAUNORUBICIN, AND VP16–213 IN ADULT PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA

Abstract The combination cytosine arabinoside (ara-C), daunorubicin, and VP16–213 was studied in 28 patients with acute non-lymphocytic leukemia to define the toxicity of the combination and assess its efficacy. Of 21 previously untreated patients, 16 (76%) achieved a complete response (CR) with the median remission duration not reached but exceeding 25 weeks. For CR patients, the median number of days with neutrophils < 500/μI was 19. The median survival for patients with CR is 60 weeks. Two of seven previously treated patients achieved CR for 11 weeks and in excess of 36 weeks, respectively. At the initial VP16–213 dose of 100 mg m^-2 per day for seven days, severe stomatitis was seen in 38% of courses but was less with dose reduction to 75 mg m^-2 per day for seven days. Other toxicity was similar to previous experience with ara-C and daunorubicin alone.     

TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION WITH A MONOCLONAL ANTIBODY TO A T CELL ANTIGEN (HuLy-m2)

Abstract The progress of five patients with recurrent renal allograft rejection who were treated with anti-HuLy-m2 (anti-T cell subset monoclonal antibody) is described. The therapy was without significant side effects and all patients responded to therapy with a diminution of OKT3⁺ and HuLy-m1⁺ (= E-RFC) peripheral blood lymphocytes. Three of the five patients had improvement in renal rejection. One patient demonstrated long term improvement in renal function, in another two patients renal function improved temporarily, and the remaining two patients had no significant benefit from anti-HuLy-m2 therapy. This limited trial has demonstrated the potential value of a monoclonal anti-T cell antibody, reactive with a subset of T cells, for immunotherapy of renal rejection in patients previously treated with anti-rejection therapy.